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See ARTICLE page XX the presence of transforming growth factor-express more CCL20 and IL-10, whereas Th 17 cells diff erentiated in the absence of transforming growth factorand in the presence of IL-1, and IL-23 express Tbx21 (T-bet), the master regulator of Th 1 cells and interferon (IFN)-along with IL-17A. In adoptive transfer experiments, IL-23-driven Th 17 cells were more pathogenic than Th 17 cells diff erentiated in the presence of transforming growth factor-. 4 Other Th 17 cells generated in vitro have been described that also express cytokines classically associated with Th 2 cells or a regulatory T-cell phenotype. 6 In addition, not only can Th 17 cells express other cytokines at the same time as IL-17A they can also stop expressing IL-17A altogether. Recent work with fate-mapping knock-in mice showed that IL-17A expression by CD4 + cells can be transient and these so-called ex-Th 17 cells can acquire the ability to express IFNand lose the abi lity to express IL-17A under certain conditions. 7 In the infl amed spinal cords of mice with EAE, T cells expressing IFN-predominantly originated from cells that previously produced IL-17A and this conversion was IL-23-dependent, whereas in an acute cutaneous infection model, T cells making IL-17A neither lose expression of IL-17A nor did these cells acquire expression of other cytokines. 7 DNAse sensitivity studies and global mapping of epigenetic markers of active and closed chromatin help explain the potential for plasticity at the molecular level as the IFN-and Tbx21 loci are poised for expression in Th 17 cells diff erentiated in vitro . 8 It appears then that the local environment and cytokine milieu at sites of infl ammation are key factors in both the development of diff erent types of Th 17 cells and their conversion into distinct subtypes with various levels of pathogenic activity.
Th17 cells are CD4 + T lymphocytes, which not only have an important role in host defense to extracellular bacteria and fungi but have also been described as uniquely pathogenic in multiple infl ammatory diseases. Th 17 cells produce a number of signature cytokines including, but not limited to, interleukin (IL)-17A, IL-17F, IL-22, and IL-21, and require expression of the transcription factor ROR t for development and IL-23 for maturation and expansion. Mouse models of inflammation provided the first evidence that IL-23-driven Th17 cells are pathogenic; in that, defi ciency of IL-23 was protective and associated with reduced IL-17A at sites of immune pathology. Furthermore, mice lacking IL-17A or IL-17RA, one of its receptor subunits, showed reduced disease in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, the collagen-induced arthritis model and in mouse models of psoriasis (PsO). Th ese preclinical data provided support for a critical role for Th 17 cells and IL-17A in the pathology associated with multiple infl ammatory diseases. Other immune cell types in particular innate lymphoid cells and T cells have subsequently been identifi ed as additional major sources of IL-17A, although their role in disease is currently less clear. 1 Recently, data for the role of IL-17A in human disease has emerged. Secukinumab (AIN457) is a fully human neutralizing antibody to IL-17A and benefi cial clinically relevant responses have been reported in patients with PsO, rheumatoid arthritis (RA), and uveitis aft er treatment. 2 Similar improved symptoms were seen in RA patients treated with another IL-17A therapeutic, LY2439821, a humanized monoclonal antibody to IL-17A. 3 Taken together these clinical data provide the fi rst evidence that IL-17A has a signifi cant role in the pathophysiology of human disease.
Th e defi nition of Th 17 cells as a single lineage has been brought into question with the description of heterogeneous populations of IL-17A-producing CD4 + T cells with various degrees of pathogenicity. 4 A recent report provides new insight into why different subsets of Th17 cells in the gut may have contradictory roles. Esplugues et al. 10 describe how proinflammatory Th17 cells can be reprogrammed in the gut to take on a regulatory function. Primarily using an anti-CD3 antibody-induced mouse model of tolerance, they fi rst demonstrate that Th 17 cells accumulate in the small intestine in response to a strong T-cell receptor stimulus. Th 17 cell accumulation is dependent on the CCL20 / CCR6 chemokine / chemokine receptor axis as well as on IL-17A / F signaling in a positive feedback loop. Th e severity of intestinal pathology in response to anti-CD3 antibody treatment correlates with accumulation of Th17 cells in the gut but the disease is transient. Remarkably, the authors found that although some cells are eliminated via the intestinal lumen, the remaining Th 17 cells in the duo denum acquire immunosuppressive properties. When the expression profi le of these regulatory Th 17 (rTh 17) cells, which are IL17A + FoxP3 − , is compared with that of Th 17 cells from the central nervous system from mice with EAE, both Th 17 cell populations have similar activation markers (CD25, CD69), but rTh 17 cells have less proinfl ammatory tumor necrosis factor-and IL-2 and more anti-infl ammatory IL-10. In fact, the suppressive capacity of the rTh 17 cells is dependent on IL-10, transforming growth factor-, and CTLA-4. Th 17 cells do not accumulate in the gut in CCR6-defi cient mice and are increased in the spleen and lymph nodes relative to wild-type mice. Furthermore, splenic Th 17 cells from CCR6-defi cient mice do not have suppressive activity implying migration to the small intestine is necessary for the acquisition of regulatory function. Th e mechanism underlying the conversion of proinfl ammatory Th 17 cells to rTh 17 cells remains to be elucidated but correlates with migration of the cells into the gut, suggesting a unique microenvironment exists in this tissue to facilitate Th 17 cell control.
Increased numbers of Th 17 cells are found in the infl amed mucosa of patients with Crohn ' s disease (CD) and ulcerative colitis as compared with normal colonic mucosa, and it has become clear that similar to the mouse models, Th 17 cells found in the gut of Crohn ' s disease patients are also heterogenic. Several studies have identifi ed a subset of Th 17 cells isolated from gut mucosa of CD patients that produce IFN-along with IL-17A. 11, 12 In addition, a subset of Th 17 cells isolated from the lamina propria of CD patients has been reported to express FoxP3 and exhibit suppressive activity. 6 Th erefore, there is overlap among Th 17, Th 1, and Treg cell lineages in the colonic mucosa of CD patients, and this heterogeneous population of gut Th17 cells that express IL-17A in combination with either IFN-or FoxP3 likely contains cells with diff erent, potentially opposing roles. Recently, results from a proof-ofconcept study with secukinumab demonstrated that blockade of IL-17A was ineff ective in patients with Crohn ' s disease and in post-hoc analyses it appeared that secukinumab in fact exacerbated disease in a subset of patients. 13 Th ese results contrast with the effi cacy reported with IL-17A inhibitors in small populations of RA, PsO, and non-infectious uveitis patients, providing additional support for a complex and potentially unique role for IL-17A and Th 17 cells in the gut.
In summary, Th17 cells, defined by expression of IL-17A, are abundantly present in multiple chronic infl ammatory and autoimmune diseases such as PsO, RA, and inflammatory bowel disease. However, recent clinical data examining the effi cacy of IL-17 inhibitors in multiple patient populations has called into question whether Th 17 cells are similarly pathogenic across diff erent diseases. Clinical trials with antibodies to IL-17A have reported benefi t in PsO, RA, and uveitis patient populations, whereas in Crohn ' s disease no clinical benefi t and some exacerbation of disease was observed, suggesting the role of Th 17 cells and IL-17A in infl ammatory bowel disease is diff erent from other infl ammatory diseases. It is clear that different subsets of Th 17 cells exist in the gut mucosa. CD4 + T cells expressing both IFN-and IL-17A appear to represent the pathogenic sub-population of Th 17 cells, whereas rTh17 cells with suppressive properties may be protective, although further characterization of the relationships between these populations is required. Th e new study from Esplugues et al. 10 suggests something specifi c about the gut environment drives Th 17 cells to acquire a protective function. Perhaps the unique exposure to innate signals in the gut due to the intense bacterial load creates a suppressive environment. Specifi c taxon of microbiota have been shown to infl uence the generation of Th 17 cells in the intestine and it would be interesting to evaluate whether the makeup of the commensal microbiome is involved in the transition of proinfl ammatory Th 17 cells to rTh 17 cells. 14 It is also possible that IL-17A has gut-specifi c homeostatic roles such as promoting the integrity of the epithelial cell barrier and regulating growth of certain pathogens. Clearly, the role for Th 17 cells and IL-17A in the gut
